{"id":43093,"date":"2019-10-15T18:55:09","date_gmt":"2019-10-15T16:55:09","guid":{"rendered":"https:\/\/newserver.fyb.de\/abalos-therapeutics-e12-million-series-a-financing\/"},"modified":"2019-10-15T18:55:09","modified_gmt":"2019-10-15T16:55:09","slug":"abalos-therapeutics-e12-million-series-a-financing","status":"publish","type":"post","link":"https:\/\/www.fyb.de\/en\/abalos-therapeutics-e12-million-series-a-financing\/","title":{"rendered":"Abalos Therapeutics: \u20ac12 million Series A financing"},"content":{"rendered":"

Essen, Germany \u2014 Abalos Thera\u00adpeu\u00adtics<\/strong> announ\u00adced the closing of a \u20ac12 million Series A finan\u00adcing round and its corpo\u00adrate debut. The company\u2019s goal is to deve\u00adlop new immuno-onco\u00adlogy thera\u00adpeu\u00adtics. This approach is based on a speci\u00adfic type of arena\u00advi\u00adrus that prefe\u00adren\u00adti\u00adally infects and repli\u00adca\u00adtes in cancer cells, gene\u00adra\u00adting a strong immune response against the cancer cells. The Series A round was jointly led by Boeh\u00adrin\u00adger Ingel\u00adheim Venture Fund<\/strong> (BIVF) and Gr\u00fcn\u00adder\u00adfonds Ruhr<\/strong> and included invest\u00adments from NRW.BANK and High-Tech Gr\u00fcn\u00adder\u00adfonds (HTGF)<\/strong>. The newly formed Super\u00advi\u00adsory Board of the company will be joined by repre\u00adsen\u00adta\u00adti\u00adves of all investors.<\/p>\n

As part of the finan\u00adcing, Abalos further announ\u00adced the appoint\u00adment of Dr. Marcus Kostka<\/strong> as Chief Execu\u00adtive Offi\u00adcer and Dr. J\u00f6rg Voll\u00admer as Chief Scien\u00adti\u00adfic Offi\u00adcer. Both have many years of expe\u00adri\u00adence in corpo\u00adrate development.<\/p>\n

\u201cAbalos\u2019 goal is to leverage the potent immune acti\u00adva\u00adtion and highly speci\u00adfic tumor tropism of arena\u00advi\u00adru\u00adses to deve\u00adlop a diffe\u00adren\u00adtia\u00adted immune-onco\u00adlogy approach and vali\u00addate it clini\u00adcally,\u201d said Marcus Kostka, M.D., CEO of Abalos Thera\u00adpeu\u00adtics. \u201cHaving alre\u00adady supported and finan\u00adced a number of biotech compa\u00adnies over the last few years, what attrac\u00adted me to Abalos in parti\u00adcu\u00adlar was the promi\u00adsing tech\u00adno\u00adlogy. The oppor\u00adtu\u00adnity to build a company toge\u00adther with J\u00f6rg Voll\u00admer, an expe\u00adri\u00aden\u00adced immu\u00adno\u00adlogy expert, also repres\u00adents an extre\u00admely attrac\u00adtive opportunity.\u201d<\/p>\n

The funding round will enable Abalos to advance its arena\u00advi\u00adrus-based drug candi\u00adda\u00adtes into clini\u00adcal vali\u00adda\u00adtion. The first product candi\u00adda\u00adtes are being deve\u00adlo\u00adped using the company\u2019s proprie\u00adtary Fast Evolu\u00adtion plat\u00adform, which gene\u00adra\u00adtes viral strains with opti\u00admal anti-tumor proper\u00adties. These candi\u00adda\u00adtes are selec\u00adted based on their poten\u00adtial to repro\u00adgram the immune system and elimi\u00adnate mali\u00adgnant tumor tissue in a targe\u00adted and effi\u00adci\u00adent manner. The approach is based on the inno\u00adva\u00adtive rese\u00adarch of immu\u00adno\u00adlo\u00adgists Prof. Dr. Karl Lang, Head of the Depart\u00adment of Immu\u00adno\u00adlogy at the Medi\u00adcal Faculty of the Univer\u00adsity of Duis\u00adburg-Essen, and Prof. Dr. Phil\u00adipp Lang, Direc\u00adtor of the Depart\u00adment of Mole\u00adcu\u00adlar Medi\u00adcine II at the Univer\u00adsity of D\u00fcssel\u00addorf. Abalos opera\u00adtes in close coope\u00adra\u00adtion with the univer\u00adsi\u00adties of Duis\u00adburg-Essen and D\u00fcsseldorf.<\/p>\n

Dr. Aris\u00adto\u00adte\u00adlis Nastos from Gr\u00fcn\u00adder\u00adfonds Ruhr commen\u00adted: \u201cWe see signi\u00adfi\u00adcant progress in the field of immuno-onco\u00adlogy, howe\u00adver, there is still a need for product candi\u00adda\u00adtes that should enable the full power of the entire immune system to be harnes\u00adsed. It is parti\u00adcu\u00adlarly important that these not only attack the primary tumor but also more distant meta\u00adsta\u00adses. We are plea\u00adsed to support Abalos\u2019 expe\u00adri\u00aden\u00adced manage\u00adment team and its dedi\u00adca\u00adted scien\u00adtists as they work towards an arena\u00advi\u00adrus-based solution.\u201d<\/p>\n

Dr. Frank Hensel, Prin\u00adci\u00adpal of High-Tech Gr\u00fcn\u00adder\u00adfonds, adds: \u201cAbalos Thera\u00adpeu\u00adtics is an excel\u00adlent exam\u00adple of first-class scien\u00adti\u00adfic achie\u00adve\u00adments at univer\u00adsi\u00adties in Germany. The combi\u00adna\u00adtion with an indus\u00adtry-expe\u00adri\u00aden\u00adced manage\u00adment team has resul\u00adted in a company that is capa\u00adble of taking a decisive step in cancer treatment.\u201d<\/p>\n

Dr. Marcus Kostka is a seaso\u00adned indus\u00adtry expert with over 20 years of expe\u00adri\u00adence in various posi\u00adti\u00adons at Boeh\u00adrin\u00adger Ingel\u00adheim (BI) where he iden\u00adti\u00adfied and drove inno\u00adva\u00adtion. Most recently, Dr. Kostka was a venture fund part\u00adner at BI and held super\u00advi\u00adsory board posi\u00adti\u00adons at seve\u00adral compa\u00adnies. He was also invol\u00adved in the successful exits of Rigon\u00adtec and ICD Therapeutics.<\/p>\n

Dr. J\u00f6rg Voll\u00admer brings to his posi\u00adtion as CSO at Abalos Thera\u00adpeu\u00adtics exten\u00adsive know\u00adledge and expe\u00adri\u00adence in the fields of immu\u00adno\u00adlogy, onco\u00adlogy and infec\u00adtious dise\u00ada\u00adses. He has acqui\u00adred these in the course of his career in various R&D and manage\u00adment posi\u00adti\u00adons. Most recently, Dr. Voll\u00admer was CSO at Rigon\u00adtec, where he was invol\u00adved in the deve\u00adlo\u00adp\u00adment of a novel immuno-onco\u00adlogy treat\u00adment approach and its clini\u00adcal vali\u00adda\u00adtion. He also led the company\u2019s R&D acti\u00advi\u00adties until its acqui\u00adsi\u00adtion by MSD in 2017.<\/p>\n

About Abalos<\/strong>
\nAbalos Thera\u00adpeu\u00adtics is using the unique immune stimu\u00adla\u00adtion of arena\u00advi\u00adru\u00adses to deve\u00adlop a new approach to fight\u00ading cancer. This should enable the full power of the entire immune system to be used speci\u00adfi\u00adcally against cancer cells. The goal of Abalos\u2019 arena\u00advi\u00adrus-based product candi\u00adda\u00adtes is to acti\u00advate the body\u2019s innate and adap\u00adtive immune response by propa\u00adga\u00adting the viru\u00adses in cancer cells. As a result, all rele\u00advant immune cell types speci\u00adfi\u00adcally attack the primary tumor and also distant meta\u00adsta\u00adses. Led by expe\u00adri\u00aden\u00adced biotech entre\u00adpre\u00adneurs and immu\u00adno\u00adlogy pioneers, Abalos aims to make a quan\u00adtum leap in immuno-oncology.<\/p>\n

About Boeh\u00adrin\u00adger Ingel\u00adheim Corpo\u00adrate Venture Fund (BIVF)<\/strong>
\nFoun\u00added in 2010, Boeh\u00adrin\u00adger Ingel\u00adheim Venture Fund GmbH (BIVF) invests in biotech\u00adno\u00adlogy compa\u00adnies focu\u00adsed on breakth\u00adrough new thera\u00adpies to drive inno\u00adva\u00adtion in biome\u00addi\u00adcal rese\u00adarch. The BIVF seeks signi\u00adfi\u00adcant impro\u00adve\u00adments in pati\u00adent care through ground\u00adbrea\u00adking scien\u00adti\u00adfic disco\u00adveries as well as their clini\u00adcal trans\u00adla\u00adtion by buil\u00adding long-term rela\u00adti\u00adonships with scien\u00adtists and entre\u00adpre\u00adneurs. The focus of the BIVF is to explore novel thera\u00adpeu\u00adtic approa\u00adches that address high unmet medi\u00adcal needs in immuno-onco\u00adlogy, rege\u00adne\u00adra\u00adtive medi\u00adcine, infec\u00adtious dise\u00ada\u00adses, and digi\u00adtal health. These concepts may include, but are not limi\u00adted to, novel plat\u00adform tech\u00adno\u00adlo\u00adgies in response to previously untreata\u00adble dise\u00ada\u00adses, next-gene\u00adra\u00adtion vacci\u00adnes, and\/or New Biolo\u00adgi\u00adcal Enti\u00adties, such as onco\u00adly\u00adtic viral therapy.<\/p>\n

The BIVF takes an active role vis-\u00e0-vis the compa\u00adnies in its port\u00adfo\u00adlio and adds signi\u00adfi\u00adcant value through its own exten\u00adsive expe\u00adri\u00adence in drug disco\u00advery, science and manage\u00adment. BIVF mana\u00adges EUR 250 million and curr\u00adently over\u00adsees a port\u00adfo\u00adlio of over 25 companies.
\nboehringer-ingelheim-venture.com.<\/p>\n

About the Gr\u00fcn\u00adder\u00adfonds Ruhr<\/strong>
\nThe Gr\u00fcn\u00adder\u00adfonds was initia\u00adted jointly by Initia\u00adtiv\u00adkreis Ruhr and NRW.BANK and is the first private-sector early-stage fund in the Ruhr region finan\u00adced by regio\u00adnal indus\u00adtrial and finan\u00adcial compa\u00adnies. The fund invests in inno\u00adva\u00adtive and tech\u00adno\u00adlogy-orien\u00adted compa\u00adnies from the life science & health, digi\u00adtal economy, chemi\u00adcals & new mate\u00adri\u00adals, energy & indus\u00adtry, and logi\u00adstics & trade sectors. Prere\u00adqui\u00adsi\u00adtes are good growth and exit pros\u00adpects as well as compe\u00adtent manage\u00adment. As a multi-corpo\u00adrate early-stage fund, it also opens up important indus\u00adtry access points for the respec\u00adtive port\u00adfo\u00adlio companies.
\ngruenderfondsruhr.com.<\/p>\n

About NRW.BANK<\/strong>
\nNRW.BANK is the deve\u00adlo\u00adp\u00adment bank for North Rhine-West\u00adpha\u00adlia. It supports its owner, the state of NRW, in its struc\u00adtu\u00adral and econo\u00admic policy tasks. In its three promo\u00adtion fields \u201cEconomy\u201d, \u201cHousing\u201d and \u201cInfrastructure\/Municipalities\u201d, NRW.BANK uses a broad range of promo\u00adtion instru\u00adments: from low-inte\u00adrest deve\u00adlo\u00adp\u00adment loans to equity finan\u00adcing and advi\u00adsory services. It works toge\u00adther with all banks and savings banks in NRW on a compe\u00adti\u00adtion-neutral basis. In its promo\u00adtion acti\u00advi\u00adties, NRW.BANK also takes into account exis\u00adting offers from the fede\u00adral govern\u00adment, the state and the Euro\u00adpean Union.
\nnrwbank.com<\/p>\n

About High-Tech Gr\u00fcnderfonds<\/strong>
\nThe seed inves\u00adtor High-Tech Gr\u00fcn\u00adder\u00adfonds (HTGF) finan\u00adces tech\u00adno\u00adlogy start\u00adups with growth poten\u00adtial. With a total volume of EUR 895.5 million distri\u00adbu\u00adted across three funds and an inter\u00adna\u00adtio\u00adnal part\u00adner network, HTGF has alre\u00adady supported more than 550 start\u00adups since 2005. His team of expe\u00adri\u00aden\u00adced invest\u00adment mana\u00adgers and startup experts supports the young compa\u00adnies with know-how, entre\u00adpre\u00adneu\u00adrial spirit and passion. The focus is on high-tech start-ups in the soft\u00adware, media and Inter\u00adnet sectors, as well as hard\u00adware, auto\u00adma\u00adtion, health\u00adcare, chemi\u00adcals and life scien\u00adces. More than EUR 2 billion in capi\u00adtal has been inves\u00adted in the HTGF port\u00adfo\u00adlio by exter\u00adnal inves\u00adtors in more than 1,400 follow-on finan\u00adcing rounds to date. The fund has also successfully sold shares in more than 100 companies.<\/p>\n

Inves\u00adtors in the public-private part\u00adner\u00adship include the German Fede\u00adral Minis\u00adtry for Econo\u00admic Affairs and Energy, KfW Capi\u00adtal, the Fraun\u00adho\u00adfer-Gesell\u00adschaft and the busi\u00adness enter\u00adpri\u00adses ALTANA, BASF, Bayer, Boeh\u00adrin\u00adger Ingel\u00adheim, B.Braun, Robert Bosch, B\u00dcFA, CEWE, Deut\u00adsche Post DHL, Dr\u00e4ger, Dril\u00adlisch AG, EVONIK, EWE AG, FOND OF, Haniel, Hettich, Knauf, K\u00f6rber, LANXESS, media + more venture Betei\u00adli\u00adgungs GmbH & Co. KG, PHOENIX CONTACT, Post\u00adbank, QIAGEN, RWE Gene\u00adra\u00adtion SE, SAP, Schufa, Schwarz Gruppe, STIHL, Th\u00fcga, Vector Infor\u00adma\u00adtik, WACKER and Wilh. Werhahn KG.<\/p>\n","protected":false},"excerpt":{"rendered":"

Essen, Germany \u2014 Abalos Thera\u00adpeu\u00adtics announ\u00adced the closing of a \u20ac12 million Series A finan\u00adcing round and its corpo\u00adrate debut. The company\u2019s goal is to deve\u00adlop new immuno-onco\u00ad\u00adlogy thera\u00adpeu\u00adtics. This approach is based on a speci\u00adfic type of arena\u00advi\u00adrus that prefe\u00adren\u00adti\u00adally infects and repli\u00adca\u00adtes in cancer cells, gene\u00adra\u00adting a strong immune response against the cancer [\u2026]<\/p>\n","protected":false},"author":2,"featured_media":43103,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[886,1364,1366],"tags":[],"class_list":["post-43093","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general-en","category-featured-en","category-news-en","news-category-venture-capital-news"],"yoast_head":"\nAbalos Therapeutics: \u20ac12 million Series A financing - FYB Financial Yearbook<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.fyb.de\/en\/abalos-therapeutics-e12-million-series-a-financing\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Abalos Therapeutics: \u20ac12 million Series A financing - FYB Financial Yearbook\" \/>\n<meta property=\"og:description\" content=\"Essen, Germany \u2014 Abalos Thera\u00adpeu\u00adtics announ\u00adced the closing of a \u20ac12 million Series A finan\u00adcing round and its corpo\u00adrate debut. The company\u2019s goal is to deve\u00adlop new immuno-onco\u00adlogy thera\u00adpeu\u00adtics. This approach is based on a speci\u00adfic type of arena\u00advi\u00adrus that prefe\u00adren\u00adti\u00adally infects and repli\u00adca\u00adtes in cancer cells, gene\u00adra\u00adting a strong immune response against the cancer […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.fyb.de\/en\/abalos-therapeutics-e12-million-series-a-financing\/\" \/>\n<meta property=\"og:site_name\" content=\"FYB Financial Yearbook\" \/>\n<meta property=\"article:published_time\" content=\"2019-10-15T16:55:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.fyb.de\/wp-content\/uploads\/2019\/10\/a-bocc88-e1571158594257.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"323\" \/>\n\t<meta property=\"og:image:height\" content=\"268\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Tatjana Anderer\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tatjana Anderer\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.fyb.de\/en\/abalos-therapeutics-e12-million-series-a-financing\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/abalos-therapeutics-e12-million-series-a-financing\/\"},\"author\":{\"name\":\"Tatjana Anderer\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\"},\"headline\":\"Abalos Therapeutics: \u20ac12 million Series A financing\",\"datePublished\":\"2019-10-15T16:55:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/abalos-therapeutics-e12-million-series-a-financing\/\"},\"wordCount\":1254,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/abalos-therapeutics-e12-million-series-a-financing\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2019\/10\/a-bocc88-e1571158594257.jpg\",\"articleSection\":[\"General\",\"Featured\",\"News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.fyb.de\/en\/abalos-therapeutics-e12-million-series-a-financing\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.fyb.de\/en\/abalos-therapeutics-e12-million-series-a-financing\/\",\"url\":\"https:\/\/www.fyb.de\/en\/abalos-therapeutics-e12-million-series-a-financing\/\",\"name\":\"Abalos Therapeutics: \u20ac12 million Series A financing - FYB Financial Yearbook\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/abalos-therapeutics-e12-million-series-a-financing\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/abalos-therapeutics-e12-million-series-a-financing\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2019\/10\/a-bocc88-e1571158594257.jpg\",\"datePublished\":\"2019-10-15T16:55:09+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.fyb.de\/en\/abalos-therapeutics-e12-million-series-a-financing\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.fyb.de\/en\/abalos-therapeutics-e12-million-series-a-financing\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/abalos-therapeutics-e12-million-series-a-financing\/#primaryimage\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2019\/10\/a-bocc88-e1571158594257.jpg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2019\/10\/a-bocc88-e1571158594257.jpg\",\"width\":323,\"height\":268},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.fyb.de\/en\/abalos-therapeutics-e12-million-series-a-financing\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.fyb.de\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Abalos Therapeutics: \u20ac12 million Series A financing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.fyb.de\/en\/#website\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"name\":\"FYB Financial Yearbook\",\"description\":\"For Your Business\",\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.fyb.de\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\",\"name\":\"FYB Financial Yearbook\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"caption\":\"FYB Financial Yearbook\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\",\"name\":\"Tatjana Anderer\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"caption\":\"Tatjana Anderer\"},\"description\":\"Gr\u00fcnderin des FYB-Verlag\",\"sameAs\":[\"http:\/\/neu.fyb.de\"],\"url\":\"https:\/\/www.fyb.de\/en\/author\/tanderer\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Abalos Therapeutics: \u20ac12 million Series A financing - FYB Financial Yearbook","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.fyb.de\/en\/abalos-therapeutics-e12-million-series-a-financing\/","og_locale":"en_US","og_type":"article","og_title":"Abalos Therapeutics: \u20ac12 million Series A financing - FYB Financial Yearbook","og_description":"Essen, Germany \u2014 Abalos Thera\u00adpeu\u00adtics announ\u00adced the closing of a \u20ac12 million Series A finan\u00adcing round and its corpo\u00adrate debut. The company\u2019s goal is to deve\u00adlop new immuno-onco\u00adlogy thera\u00adpeu\u00adtics. This approach is based on a speci\u00adfic type of arena\u00advi\u00adrus that prefe\u00adren\u00adti\u00adally infects and repli\u00adca\u00adtes in cancer cells, gene\u00adra\u00adting a strong immune response against the cancer […]","og_url":"https:\/\/www.fyb.de\/en\/abalos-therapeutics-e12-million-series-a-financing\/","og_site_name":"FYB Financial Yearbook","article_published_time":"2019-10-15T16:55:09+00:00","og_image":[{"width":323,"height":268,"url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2019\/10\/a-bocc88-e1571158594257.jpg","type":"image\/jpeg"}],"author":"Tatjana Anderer","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Tatjana Anderer","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.fyb.de\/en\/abalos-therapeutics-e12-million-series-a-financing\/#article","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/abalos-therapeutics-e12-million-series-a-financing\/"},"author":{"name":"Tatjana Anderer","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce"},"headline":"Abalos Therapeutics: \u20ac12 million Series A financing","datePublished":"2019-10-15T16:55:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.fyb.de\/en\/abalos-therapeutics-e12-million-series-a-financing\/"},"wordCount":1254,"commentCount":0,"publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"image":{"@id":"https:\/\/www.fyb.de\/en\/abalos-therapeutics-e12-million-series-a-financing\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2019\/10\/a-bocc88-e1571158594257.jpg","articleSection":["General","Featured","News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.fyb.de\/en\/abalos-therapeutics-e12-million-series-a-financing\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.fyb.de\/en\/abalos-therapeutics-e12-million-series-a-financing\/","url":"https:\/\/www.fyb.de\/en\/abalos-therapeutics-e12-million-series-a-financing\/","name":"Abalos Therapeutics: \u20ac12 million Series A financing - FYB Financial Yearbook","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.fyb.de\/en\/abalos-therapeutics-e12-million-series-a-financing\/#primaryimage"},"image":{"@id":"https:\/\/www.fyb.de\/en\/abalos-therapeutics-e12-million-series-a-financing\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2019\/10\/a-bocc88-e1571158594257.jpg","datePublished":"2019-10-15T16:55:09+00:00","breadcrumb":{"@id":"https:\/\/www.fyb.de\/en\/abalos-therapeutics-e12-million-series-a-financing\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.fyb.de\/en\/abalos-therapeutics-e12-million-series-a-financing\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/abalos-therapeutics-e12-million-series-a-financing\/#primaryimage","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2019\/10\/a-bocc88-e1571158594257.jpg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2019\/10\/a-bocc88-e1571158594257.jpg","width":323,"height":268},{"@type":"BreadcrumbList","@id":"https:\/\/www.fyb.de\/en\/abalos-therapeutics-e12-million-series-a-financing\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fyb.de\/en\/"},{"@type":"ListItem","position":2,"name":"Abalos Therapeutics: \u20ac12 million Series A financing"}]},{"@type":"WebSite","@id":"https:\/\/www.fyb.de\/en\/#website","url":"https:\/\/www.fyb.de\/en\/","name":"FYB Financial Yearbook","description":"For Your Business","publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fyb.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.fyb.de\/en\/#organization","name":"FYB Financial Yearbook","url":"https:\/\/www.fyb.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","caption":"FYB Financial Yearbook"},"image":{"@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce","name":"Tatjana Anderer","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","caption":"Tatjana Anderer"},"description":"Gr\u00fcnderin des FYB-Verlag","sameAs":["http:\/\/neu.fyb.de"],"url":"https:\/\/www.fyb.de\/en\/author\/tanderer\/"}]}},"_links":{"self":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/43093","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/comments?post=43093"}],"version-history":[{"count":0,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/43093\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media\/43103"}],"wp:attachment":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media?parent=43093"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/categories?post=43093"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/tags?post=43093"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}